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1. ABSTRACT 
Degree project, Programme in Medicine, Extracellular cAMP as a Regulator of 
lipolysis in Adipocytes, Jonathan Terling, 2017, Sahlgrenska Academy, Department of 
Metabolic Physiology, Gothenburg, Sweden. 
Introduction: Obesity is a major cause of morbidity and mortality globally. 
Understanding the mechanisms linking obesity to morbidity and the role of adipose 
tissue in human metabolism is essential to combat this threat. Research shows that the 
second messenger cyclic adenosine monophosphate (cAMP) can be released by the 
liver and exert endocrine effects on renal tubule cells causing natriuretic and 
phosphaturic effects. Extracellular cAMP has also been shown increase fatty acid 
oxidation in hepatocytes. This urged us to investigate the possible regulatory effect of 
extracellular cAMP on adipose tissue metabolism.  
Objective: To test whether extracellular cAMP affects lipolysis in adipocytes 
Methods: 3T3-L1 cells were cultured and differentiated into mature adipocytes using 
conventional methods and thereafter exposed to different cAMP concentrations for 
three hours. Effects from blockage of cAMP degradation was tested by adding the 
ecto-5’nucleotidase inhibitor AMP-CP. Glycerol released into the medium was 
quantified as a marker of lipolysis. All data were normalized to intracellular protein 
levels to avoid possible variation from uneven adipocyte distribution between culture 
wells. 
Results: cAMP increased lipolysis at a concentration of 200nM. At lower 
concentrations of cAMP (between 1-100nM), lipolysis was instead decreased or 
unchanged. AMP-CP, either alone or in combination with 200nM, had no effect on 
lipolysis, 
Conclusion/Discussion: These results suggest that cAMP both can stimulate and 
inhibit lipolysis. One possibility is that extracellular cAMP is converted to adenosine, 
which in turn activates adenosine receptors A1 and A2a expressed on adipocytes. 
Adenosine receptor A1 inhibits lipolysis whereas A2a stimulates lipolysis. A1 
receptors are more abundant in adipocytes and may therefore require lower 
concentrations to cause this anti-lipolytic effect, while A2a may be more potent 
overruling the effect of A1 at higher concentrations. Alternatively, cAMP affects 
lipolysis directly through a yet unknown receptor. 
Key Words: cAMP, Lipolysis, Cyclic AMP receptors, 3T3-L1 adipocytes, Obesity. 
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2. INTRODUCTION 
2.1. OBESITY 
Human ingenuity creates leverage for our inherent behaviours and biological needs 
such as social interaction, warmongering and eating. We create smoke signals, letters 
and social media for communication; weapons for war and advanced food systems for 
creation of food abundance. Not inherently good or bad such leverage cause change in 
a society. Between the years 1980-2013 the global prevalence of overweight people 
changed from 28.8% to 36.9% and 29.8% to 38% men and women respectively (1). 
Addressing the global obesity epidemic, the World Health Organizations (WHO) 
Global Health Observatory (GHO) writes “In 2016, 39% men and 40% of women 
aged 18+ were overweight (BMI ≥ 25 kg/m2) and 11% of men and 15% of women 
were obese (BMI ≥30 kg/m2)”. WHO also states that both overweight and obesity 
increase the likelihood of developing the metabolic syndrome and are linked to 
increased risk for cardiovascular disease, type II diabetes mellitus, malign neoplasms 
of several kinds, hypertension and cerebrovascular disease. Noticing this worrying 
trend of increased obesity and its related diseases the WHO in 2013 called for a zero 
increase in obesity. This goal however is far from achieved as obesity is increasing in 
spite of implementation of policies promoting healthy foods, physical activity and 
other obesity combating strategies of some scale worldwide. Policies as of yet show 
little effect on the obesity pandemic, but clinical interventions against the resulting 
metabolic syndrome are ever increasing in potency. In the year 2015 obesity 
contributed to 4 million deaths and 120 million disability adjusted life years, and the 
leading causes of deaths related to obesity are cardiovascular disease causing 2.7 
million deaths per 2015 and type II diabetes mellitus causing 0.6 million deaths per 
2015 (2).  
Mounting evidence suggests the importance of healthy adipose tissue for normal 
physiological function and evasion of disease. This is exemplified by both obesity and 
adipose tissue deficiency being closely tied to cardiovascular disease and the 
metabolic syndrome (3).  Expansion of adipose tissue is mediated through increased 
size and number of adipocytes, both processes being affected by inflammation. 
Inflammation, although typically seen as something deleterious, is in its acute form 
required for angiogenesis and remodelling of extracellular matrix without which 
adipose tissue will not maintain a functional endocrine and immunological profile. 
Inability to mount a potent pro-inflammatory response reduces the ability of adipose 
tissue to expand in response to excess caloric intake. This leads to ectopic fat 
deposition and chronic inflammation, and such maladaptive adipose tissue favours 
hypertrophy over hyperplasia (4). Fat deposited in other organs than adipocytes will 
cause damage depending on location with consequences such as liver steatosis, so 
called “leaky gut” i.e. defects in tight junctions in the gut allowing less restricted 
transport between gut and circulation and deteriorated metabolic profile. The 
consequences of and the risk of developing maladaptive adipose tissue is to a large 
extent likely dependent on genetic factors 
2.2. ADIPOSE TISSUE  
Adipose tissue functions as an energy reservoir, endocrine organ (5, 6), producer of 
factor C3, B and D of the complement system (7) and location for non-shivering 
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thermogenesis (8). Adipose tissue is distributed in multiple depots around the body 
and each depot consists of mainly either white, brown and beige adipocytes each with 
different functions (9). Besides adipocytes, adipose tissue is also constituted by 
immune cells, nerve cells, extracellular matrix and stroma-vascular cells (10). 
Adipose tissue secretes a wide range of hormones such as leptin, adiponectin, 
Acylation Stimulation Protein and Tumor Necrosis Factor alpha (TNF-α). Leptin is an 
important regulator of satiety. Adiponectin has antidiabetic, anti-inflammatory and 
anti-atherogenic effects through e.g. its positive effect on insulin sensitivity, 
inhibitory effect on smooth muscle cell migration in vascular walls and inhibitory 
effect on foam cell formation. Acylation Stimulation Protein causes increased cellular 
intake and esterification of Free Fatty Acids (FFA), causes translocation of Glucose 
Transporter (GLUT) proteins to the cell surface and increase LPL activity. TNF-α is a 
pro-inflammatory cytokine that causes insulin resistance (6, 11).  
Triacylglycerides (TAG) is the main compound for long-term storage of energy in the 
mammalian body. Total mass of TAG in adipocytes is dictated by integration of long 
term energy balance (10) and the balance between processes for fatty acid deposition 
and mobilization. 
Brown adipocytes function mainly as thermogenic cells and are of a different lineage 
than white and beige adipocytes. Thermogenesis is mediated by mitochondria 
expressing uncoupling protein 1 (UCP-1) in their inner membranes. UCP-1 uncouples 
the electron transport chain from ATP-synthesis and instead of ATP heat is generated. 
Brown adipose tissue (BAT) is primarily present in mammalian newborns as an 
evolutionary response to their need to maintain body temperature at birth. Since it was 
discovered much hope has been placed in this tissue as a means to increase passive 
energy expenditure to reduce obesity (12). The main approach for recruitment of 
brown adipose tissue is cold exposure that, as of yet, lacks evidence for clinically 
relevant effects in humans. BAT is however known to be regulated by parathyroid 
hormone and thereby play a role in cancer cachexia (13).  
Browning is a process in which some white adipocytes approach the brown phenotype 
with increased number of mitochondria and up regulation of UCP-1. Browned white 
adipocytes are called beige adipocytes and are thought to be of a distinct 
developmental origin. Several studies show that browning improves whole-body 
metabolic function through increased uptake of nutrients from the blood stream - 
although the effect of browning on weight loss may be modest.  
These metabolic and endocrine functions make adipose tissue a master regulator of 
metabolism with capacity for storage and expulsion of lipids, regulation of insulin 
sensitivity and satiety affecting caloric intake.  
2.3. FATTY ACID MOBILIZATION AND DEPOSITION 
Lipid droplets in adipocytes constitute the main storage facility for TAG, cholesterol 
and cholesterol esters; bound to the lipid-droplet are lipid droplet-associated proteins 
of different classes defined by Liu et al. as structural proteins, proteins responsible for 
lipid metabolism, membrane traffic, signalling and miscellaneous proteins (14). Due 
to the complexity and wide array of functions the lipid droplet-associated proteins 
display Liu et al propose a new name for the lipid droplet, the “Adiposome”. That 
name more closely mirrors the Adiposomes’ function as a metabolic organelle. 
Proteins in the structural group - such as perilipin - regulate access for TAG lipases to 
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the substrates stored in the adiposome, thus regulating basal lipolytic rate. When 
phosphorylated, perilipin will move and grant access to Hormone Sensitive Lipase 
(HSL) and Adipose Tissue Triglyceride Lipase (ATGL) (15). 
Mobilization of Free Fatty Acids (FFA) is initiated by adherence of ATGL or HSL to 
the adiposome and subsequent hydrolysis of TAG into a diacylglyceride (DAG) in a 
reaction catalyzed by ATGL or HSL (16). DAG is hydrolyzed into mono-
acylglyceride (MAG) by HSL and the last fatty acid is released from MAG by 
hydrolysis catalyzed by Monoacylglyceride Lipase (MGL), See “figure 1”. This chain 
of hydrolysis results in three FFA and glycerol. The rate-limiting step in mobilization 
of fatty acids is hydrolysis of TAG into DAG, which is mainly mediated by ATGL in 
turn regulated by glucocorticoids among other hormones. Hydrolysis of DAG is 10 to 
30-fold higher than hydrolysis of TAG (17). ATGLs’ degree of activity seems to be 
mainly regulated by access to the adiposome (18).    
 
FIGURE 1. MOBILIZATION OF FREE FATTY ACIDS 
The only DAG lipase identified in adipocytes is HSL, which is tightly regulated by 
phosphorylation. HSL can be phosphorylated at three sites which will each increase 
HSLs hydrophobic area and thus increase binding of hydrophobic substrates (19). 
HSL is phosphorylated by Protein Kinase A (PKA), which is activated by intracellular 
cAMP derived from activated Adenylyl Cyclase (AC). AC activity is increased by 
activation of GsPCRs such as the β3-adrenergic receptor or glucagon receptor and 
decreased by activation of GiPCRs such as the A1 adenosine receptor. Stimulation of 
the insulin receptor will activate Protein Phosphatase 2A (PP2A) that 
dephosphorylates HSL and phosphodiesterase 3B (PDE3B) that will degrade 
intracellular cAMP, thus decreasing activation of HSL via PKA. 
Adipose tissue has low capacity for de novo lipogenesis and thus fatty acids deposed 
in adipocytes originate either from lipogenesis in the liver or ingestion with 
subsequent transportation to the adipose tissue via lipoproteins (20). However, TAG 
in adipocytes grown in vitro is mainly derived from lipogenesis. Ingested lipids are 
taken up in the intestine and transported to the liver via chylomicrons. Lipoproteins 
are synthesized by the liver and carry TAG and cholesterol between liver and other 
tissues. From the liver TAG-rich VLDL is secreted into the inferior vena cava and 
enters the circulation. Lipoprotein lipase (LPL) bound to cellular membranes of, 
among other cell types, adipocytes and endothelial cells, catalyze hydrolysis of 
lipoprotein bound TAG and release FFAs from the glycerol backbone of TAG. FFAs 
are then transported through the cellular membrane; See “figure 2”.  
Transport of fatty acids across the cell membrane is either mediated by proteins or via 
the “flip-flop” mechanism. The proteins are split into two groups mediating either 
constitutive uptake - like the protein FAT/CD36 (21) - or induced uptake like the 
protein FATP4 (22). The flip-flop mechanism means incorporation of a fatty acid in 
the outer layer of the cell membrane followed by a turnover in the phospholipid 
bilayer placing the fatty acid in the inner layer. From there the fatty acid is free to 
enter the cell (23).  
ATGLTAG HSL
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FIGURE 2. FATTY ACID TRANSPORT AND STORAGE 
Lipogenesis is a process mainly occurring in the liver where several molecules of 
acetyl-CoA are fused and made into acyl-CoA. Acetyl-CoA is derived from 
carbohydrate catabolism directly and protein catabolism via citrate production in the 
mitochondria. Citrate can pass from mitochondria to the cytoplasm where it will be 
metabolized into acetyl-CoA and oxaloacetate. Seven acetyl-CoA will react via 
acetyl-CoA Carboxylase to create malonyl-CoA, which will bind to Acyl Carrier 
Protein (ACP); this molecule can further react to create fatty acids of different length.  
FFA in cells can 1) act as ligands for transcription factors regulating metabolic 
pathways and 2) be used catabolically in β-oxidation or 3) anabolically for 
reesterification to TAG and subsequent storage in Adiposomes, synthesis of 
membrane lipids or signalling molecules (23). β-oxidation will yield 1 acetyl-CoA + 1 
NADH + 1 FADH2 per cycle resulting in approximately 19 ATP per cycle.  
In concentrations as low as 90pmol/L insulin inhibits half of fatty acid mobilization 
compared to 200pmol/L needed to cause a 50% decrease in glucose mobilization (24). 
Insulin will cause increased activity in LPL, dephosphorylation of HSL via activation 
of PP2A, increased reesterification of fatty acids through activation of acetyl-CoA 
carboxylase and Fatty Acid Synthase (FAS) (23), increased hydrolysis of cAMP 
through activation of PDE3B, increased glycolysis resulting in increased amounts of 
substrates for lipogenesis and cause translocation of FATP1/4 and FAT/CD36 to the 
cellular membrane (21, 22).  
2.4. CAMP 
Since 1958 when the first article describing cAMP as an 
intracellular signal transducer (25) was published, the role 
of cAMP within the cell has been thoroughly researched. 
cAMP has risen to be recognized as a universal regulator of 
cell function with effects dependent on location in the 
organism as well as concentration. Active processes for 
efflux of cAMP from cells in general as a response to AC 
activation have been known since 1963 (26) and is known in 
adipocytes (27). These processes have mainly been thought 
of as means to control intracellular cAMP levels or initiate 
the cAMP-adenosine pathway (28). Several articles have 
shown effects from extracellular cAMP on various tissues 
such as proximal renal tubule epithelial cells (29) and 
hepatocytes (30). This urged us to explore the role of 
extracellular cAMP in the regulation of adipocyte 
metabolism. 
TAG bound to VLDL is 
secreted by the liver
• VLDL and LDL 
circulates to target 
tissue
Lipoprotein lipase 
hydrolyses TAG
• Free fatty acids pass 
cell membranes in a 
protein and non-
protein dependent 
way
TAG is reesterified from 
3 fatty acids and glycerol 
from inside the cell
• TAG is stored in the 
adiposome
Activation of GPCR and 
dissociation of the α-
subunit.
The α-subunit interacts 
with AC and depending on 
G-protein type either 
increases or decreases AC 
activity causing altered 
levels of intracellular cAMP
cAMP activates PKA that 
will phosphorylate several 
proteins responsable for 
glycogenolysis, lipolysis and 
gluconeogenesis.
FIGURE 3 CAMP PATHWAY 
 9 
cAMP is produced by AC of nine membrane bound varieties that are regulated by G-
Protein Coupled Receptors (GPCR), see figure 3. GPCRs are internally bound to 
either stimulatory G-proteins (Gs) increasing cAMP production or inhibitory G-
proteins (Gi) inhibiting cAMP production via regulation of ACs. Gs and Gi proteins 
are heterotrimeric consisting of α-, β- and γ-subunits. In trimeric form the α-subunit is 
bound to GDP that will be replaced by GTP following activation of associated GPCR, 
causing dissociation of the subunit and its subsequent interaction with AC. Gs and Gi 
proteins will each counteract the effects of the other (31). cAMP either interacts with 
targets inside the cell with subsequent degradation by PDE3B and is reused in ATP 
synthesis or leave the cell via Multidrug Resistance-associated Protein 4 (MPR4) (32). 
Outside the cell Ecto-phosphodiesterase (Ecto-PDE) and Ecto-5’nucleotidase 
sequentially convert extracellular cAMP into adenosine. Adenosine either binds A2 
receptors leading to an increase in cAMP production or A1/3 receptors attenuating 
cAMP production making expulsion of cAMP important in autocrine and paracrine 
signalling (28). Phosphodiesterases are found in close proximity to cells but only in 
trace amounts in the blood, making cAMP in circulation stable (29). Physiological 
concentration of cAMP in mammalian plasma ranges between 10-50 nM (29).  
G-protein coupled cAMP receptors (CaR1-CaR4) have been identified in the 
Dictyostelium discoideum amoeba but no homologous protein has been found in 
mammalians. Sequence similarities between CaR1-CaR4 and the mammalian secretin 
receptors are however apparent of which the parathyroid hormone receptor (PTH1R) 
is the most similar (29). Activation of PTH1R causes lipolysis, browning and change 
of preferred energy substrate from carbohydrates to fats in adipocytes (33). It is thus 
possible that cAMP through PTH1R can cause similar effect.  
Hepatocytes stimulated by glucagon will increase cAMP production and efflux 
leading to increased levels of cAMP both intra- and extracellularaly. Glucagon is 
known to increase transcription of gluconeogenic genes such as Glucose-6 
phosphatase (G6Pase) and Phosphoenolpyruvate carboxykinase (Pepck) via 
intracellular cAMP activating PKA, in turn phosphorylating cAMP-responsive 
element-binding protein (CREB). However, glucagon stimulation also induces 
expression of the genes for Carnitine Palmitoyltransferase 1a (Cpt1a) and Acyl-
Coenzyme A oxidase (Aox) via extracellular cAMP. Mechanisms for efflux of cAMP 
are up-regulated leading to increased extracellular cAMP that is subsequently 
metabolized into adenosine. Adenosine will pass through the cell membrane via the 
transporter CNT2 and activate AMP-Activated Protein Kinase (AMPK) which in turn 
activates PPARα (30). AMPK regulates genes associated with cellular metabolism 
causing effects including inhibition of lipogenesis and stimulation of hepatic and 
muscular gluconeogenesis and fatty acid oxidation. Among up-regulated genes are 
Cpt1a and Aox (34). Cpt1a helps transfer fatty acids into the mitochondria for 
oxidation and Aox mediates a step in fatty acid oxidation. Activation of these genes 
thus leads to increased fatty acid oxidation giving more substrate for gluconeogenesis. 
By inducing fatty acid metabolism in vivo cAMP injections reduced development of 
obesity induced liver steatosis in mice (30).  This is an example of the importance of 
the cAMP-adenosine pathway. 
In the kidney, liver-derived extracellular cAMP inhibits reabsorption of phosphate 
and sodium in the proximal tubule (29). The mechanism for this effect is unknown, 
but cAMP has been shown to adhere to cell membranes of proximal tubule cells, as 
well as other cell types (35), opening the possibility of cAMP-receptors being present 
(36). The phosphaturic and natriuretic effects suggest inhibition of the Na-Pi 
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cotransporter that is also inhibited by parathyroid hormone (PTH). In contrast to the 
proposed mechanism for extracellular cAMP in liver, cAMP degradation into AMP is 
not extensive in the kidney thus making it unlikely that the effect is mediated via 
adenosine (37). Indeed, renal tissue perfused with adenosine shows altered 
reabsorption while addition of cAMP causes increased diuretic effect even in such a 
setting. This implies that extracellular cAMP can exert direct effects that are 
independent on AMP/adenosine.  
2.5. PARATHYROID HORMONE 
The main physiological role of Parathyroid Hormone (PTH) is regulation of calcium 
and phosphate concentrations in the blood via effects on bone formation, gut 
absorption and renal tubular uptake. PTH is regulated by calcium concentration in 
blood.  
PTH has been shown to activate HSL via the PKA pathway (39) and increases in PTH 
are linked to metabolic disease such as type II diabetes, cardiovascular disease and 
cachexia in cancer and chronic kidney disease. Moreover PTH has been shown to 
induce browning in adipocytes causing increased expression of UCP-1 (13). Taken 
together, PTH increases lipolysis and thermogenesis in adipose tissue in addition to its 
well-established effects on calcium and phosphate metabolism.  
2.6. AIM  
This study aims to test whether extracellular cAMP affects lipolysis in adipocytes. 
3. MATERIALS AND METHODS 
3.1. CELL CULTURE 
3T3-L1 cells were differentiated into adipocytes using conventional protocols (40) 
and were used in all experiments in this study. Cells were grown in 12-well plates and 
experiments were carried out 1-3 days after full differentiation. A functional 
adipocyte phenotype is suggested by a pro-lipolytic action of β3 adrenergic receptor 
agonists and an anti-lipolytic action of insulin. 
3.2. CAMP STIMULATION 
The aim of the experiment is to run a cAMP dose-response experiment, exposing 
3T3-L1 adipocytes to cAMP at different concentrations in an insulin- and adenosine-
deprived setting. 12 hours prior to addition of cAMP, cells were cultured in serum 
free DMEM 10% BSA in order to negate any anti-lipolytic effect from insulin present 
in the fetal bovine serum in the regular growth medium. After rinsing wells with PBS, 
the cells were incubated at 37C with cAMP at concentrations ranging from 1-200 
nM, β3 adrenergic receptor agonists (CL316,243, 1µM) or control in 300 µL KRHG 
buffer without adenosine for 180 minutes 100µL of culture media was aspirated after 
180 minutes and cells were lyzed by adding homogenisation buffer.  
3.3. CO-STIMULATION WITH INSULIN OR AMP-CP 
The aim of the experiment is to stimulate 3T3-L1 cells with cAMP + AMP-CP/insulin 
in an otherwise insulin- and adenosine-deprived setting. 12 hours prior to addition of 
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cAMP and co-stimulants, cells were cultured in serum free DMEM 10% BSA in order 
to negate any anti-lipolytic effect from insulin present in the fetal bovine serum in the 
regular growth medium. After rinsing cells with PBS, KRHG buffer without 
adenosine was added to the wells. The ecto-5’nucleotidase inhibitor AMP-CP (100 
uM) or insulin (0.1 uM) was added to the medium prior to addition of cAMP (200nM). 
After 180 minutes incubation at 37C 100uL of culture media was aspirated and cells 
were lyzed by adding homogenizsation buffer.  
3.4. GLYCEROL AND PROTEIN MEASUREMENTS 
Samples from all wells were analysed in duplicates on 96 well half-area microplates 
from Corning.  
To assess the lipolytic effect of extracellular cAMP, glycerol was measured by “Free 
glycerol reagent” in the cell culture medium. Samples were diluted 1:2 in KRHG and 
incubated with reagent for 30 minutes. An absorbance analysis was carried out at 
540nM in a spectrometer (SpectraMax i3x). Duplicates with internal deviation larger 
than SD=0.05 were excluded. See Figure 7 in “Figures and appendices” section for a 
typical standard graph.  
In the cAMP “dose-response” experiment, glycerol values were corrected for protein 
content of cell lysates to negate differences in glycerol concentration due to varying 
number of cells in the wells. Cell lysates were produced by adding homogenisation 
buffer to wells followed by scraping with a cell scraper and aspiration to tubes. Tubes 
were spun at 4 °C, 10G for 10 minutes to remove debris. Protein was measured in the 
supernatant using the “PierceTM BCA Protein Assay Kit”. Protein measurement was 
not done in the AMP-CP or insulin co-stimulation experiments as protein samples 
went missing in the lab freezer.  
3.5. REAGENTS AND CHEMICALS 
For cell culture, 12-well plates were acquired from Sarstedt. Cells of the 3T3 cell line 
were acquired from other members of the lab. “Dulbeccos’ modified eagles’ medium” 
(DMEM) was acquired from Thermo-Fisher, Dexamethasone from Sigma, insulin 
(Actrapid) from Novo Nordic, BIX from Sigma, Newborn calf serum from Gibco, 
fetal bovine serum from Hyclone. For cell stimulation experiments KRHG buffer 
without adenosine was made from stock solutions, BSA was acquired from Sigma, 
AMP-CP was acquired from Tocris, insulin was acquired from Sigma, cAMP was 
acquired from Sigma, CL316,243 (CL) from Tocris and cell scrapers from Sarstedt. 
Homogenisation buffer including phosphorylation inhibitors (Phosstop and Complete) 
was freshly made from stock solutions. For quantification of glycerol “Free glycerol 
reagent F6428” was acquired from Sigma-Aldrich. Protein measurement was 
performed with “PierceTM BCA Protein Assay Kit”. The spectrometer used for 
glycerol and protein quantification was a SpectraMax i3x (Molecular Devices). 
3.6. DEFINING THE PROTOCOL 
Several repeats of different experimental setups were performed to optimize our 
protocol for the purpose of this study i.e. measuring the effect of cAMP on lipolysis. 
Initially culture medium was sampled three times during a 180 minutes period of 
incubation leading to successively reduced volumes of medium left to dilute 
metabolic waste products from cells. Possibly this could cause feedback interfering 
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with the results even when changed volumes are corrected for mathematically. Next 
the 12-hour period of serum free growth prior to stimulation was established as Fetal 
Bovine Serum (FBS) used in cell culture containing insulin, which effectively reduce 
lipolysis for a considerable time. Minor changes to stimulation and extraction 
procedures were added continuously with alterations such as tight sealing of cell 
plates during incubation and thorough cleansing of cell scraper between wells instead 
of changing of scraper. All experiments presented were performed under the same 
conditions using the protocol described above. 
3.7. STATISTICS  
Results are reported as ratios of glycerol in intervention samples to control samples ± 
SEM. In the dose-response experiment differences between control and intervention 
groups were assessed using Mann - Whitney U test as our values likely will not 
assume normal distribution. In co-stimulation experiments with AMP-CP or insulin 
all groups were compared with each other using the same Mann – Whitney U test. A 
P-value of <0.05 was considered statistically significant. The number of wells 
stimulated and analysed for each concentration is noted as “n” in the tables.  
Power analysis was done retrospectively as pre-test estimation of variance was not 
possible. For the dose-response experiment, power analysis was performed using the 
website “openepi.com” using the power analysis of mean difference. Confidence 
interval was set to 95% and each intervention groups’ mean, amount of samples and 
standard deviation was put in manually and compared to the control group (0nM). For 
costimulation with insulin experiments the same procedure was used but all groups 
were compared against each other. Power analysis for costimulation with AMP-CP 
was not performed as no significant differences were found.  
4. ETHICS 
All experiments were performed on 3T3-L1 cells. No ethical conflicts were identified.  
5. RESULTS  
5.1. EXTRACELLULAR CAMP BOTH REDUCED AND INDUCED LIPOLYSIS 
Extracellular cAMP significantly reduced lipolysis at a concentration of 1nM and 
100nM though power analysis showed a power of 78% for the 100nM group. In 
contrast, lipolysis was significantly increased when adipocytes were exposed to 
200nM; See table 1 and figure 4. 1uM β3 adrenergic receptor agonist (CL) induced 
lipolysis most potently and served as a positive control indicating that the adipocytes 
have functional pathways for lipolysis. Significant results were not present when 
glycerol was not normalised to protein.  
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TABLE 1 GLYCEROL IN GROWTH MEDIUM PRESENTED AS RATIOS OF GLYCEROL IN SAMPLE TO 
NEGATIVE CONTROL. 
 
GROUPS MARKED WITH RED ARE NOT SIGNIFICANTLY DIFFERENT FROM 0NM CAMP. POWER VALUES 
MARKED WITH RED ARE BELOW 80%. CAMP (CYCLIC ADENOSINE MONOPHOSPHATE). “N” IS THE 
NUMBER OF WELLS ANALYSED. 
 
FIGURE 4. CONCENTRATIONS OF GLYCEROL IN GROWTH MEDIUM OF CELLS EXPOSED TO INCREASING 
CONCENTRATIONS OF CAMP AS RATIOS OF GLYCEROL IN CONTROL. B3 STIMULATION (CL) IS A 
POSITIVE CONTROL. VALUES ARE NORMALISED TO PROTEIN AND CONTROL. CAMP (CYCLIC 
ADENOSINE MONOPHOSPHATE). SIGNIFICANT CHANGE IN RELATION TO CONTROL IS SEEN IN GROUPS 
1NM (DECREASE), 200NM (INCREASE) AND B3 (INCREASE).  
6. BLOCKADE OF CAMP METABOLISM DID NOT ALTER 
LIPOLYSIS 
No significant differences in lipolysis were seen when blocking cAMP degradation 
with AMP-CP, see table 3 and figure 5. In this experiment 200nM cAMP did not 
show increased lipolysis compared to control. Furthermore, these data were not 
normalized to protein levels. 
 
TABLE 2. THE AVERAGE GLYCEROL VALUE FOR EACH GROUP NORMALISED TO H2O IS DISPLAYED. CI 
95% DISPLAYS THE 95% CONFIDENCE INTERVAL. N DISPLAYS NUMBER OF SAMPLES IN EACH GROUP. 
Additive 
Average CI 95% n 
cAMP + AMP-CP 1.01 0.93 - 1.11 3 
cAMP 200nM 0.99 0.96 - 1.03 3 
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H2O AMP-CP 0.96 0.89 - 1.03 3 
H2O 1.00 0.95 - 1.04 3 
“N” IS THE NUMBER OF WELLS ANALYSED. 
TABLE 3. P-VALUES CALCULATED WHEN COMPARING EACH GROUP TO EACH OF THE OTHER GROUPS. 
 
VALUES ARE P-VALUES.  
 
 
 
 
 
 
 
6.1. CO-STIMULATION WITH INSULIN  
 No significant differences in lipolysis were seen when co-stimulating with insulin, 
see table 5 and figure 6. These data were not normalized to protein levels. 
TABLE 4. THE AVERAGE GLYCEROL VALUE FOR EACH GROUP NORMALISED TO H2O  IS DISPLAYED. CI 
95% DISPLAYS THE 95% CONFIDENCE INTERVAL. N DISPLAYS NUMBER OF SAMPLES IN EACH GROUP. 
Additive Average CI 95% n 
cAMP 200nM + insulin 0.98 0.85-1.12 3 
0.85
0.9
0.95
1
1.05
1.1
cAMP 200nM + AMP-
CP
cAMP 200nM H2O AMP-CP H2O
Glycerol levels 
Normalised to control
FIGURE 5. LEVELS OF GLYCEROL IN EACH GROUP. VALUES ARE DIVIDED BY THE MEAN OF THE 
H2O GROUP. NO SIGNIFICANT DIFFERENCES WERE FOUND.  
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cAMP 200nM 1.04 1.01 - 1.08 3 
H2O + insulin 0.91 0.90 - 0.92 3 
H2O 1 0.96 - 1.03 3 
“N” IS THE NUMBER OF WELLS ANALYSED. 
TABLE 5. P-VALUES CALCULATED WHEN COMPARING EACH GROUP TO EACH OF THE OTHER GROUPS. 
 
RED BOXES INDICATE INSIGNIFICANT DIFFERENCE BETWEEN COMPARED GROUPS. GREEN BOXES 
INDICATE SIGNIFICANT DIFFERENCE BETWEEN COMPARED GROUPS. VALUES ARE P-VALUES.  
 
TABLE 6 POWER CALCULATIONS CAMP-INSULIN COSTIMULATION 
 
POWER VALUES ABOVE 80% ARE MARKED WITH GREEN. 
 
 
FIGURE 6. LEVELS OF GLYCEROL IN EACH GROUP. VALUES ARE DIVIDED BY THE MEAN OF THE H2O 
GROUP. THE H20 + INSULIN GROUP IS SIGNIFICANTLY DIFFERENT FROM GROUPS H2O AND CAMP 20NM. 
 
7. DISCUSSION AND CONCLUSION 
0.8
0.85
0.9
0.95
1
1.05
1.1
cAMP 200nM +
insulin
cAMP 200nM H2O insulin H2O
Glycerol levels 
Normalised to protein and control
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The pattern where low concentrations of cAMP (1nM and tendencies at 100 nM) 
decrease while high concentrations (200 nM) increase lipolysis might be due to 
several superimposed mechanisms. Lipolysis inhibition might be mediated via 
adenosine receptor A1, while the lipolysis stimulatory effect might be due to 
stimulation of adenosine receptor A2a, uptake of adenosine via CNT2 or a yet 
unidentified membrane bound receptor with affinity for cAMP, possibly the PTHR. 
7.1. ADENOSINE RECEPTORS 
Adenosine has emerged as an important factor in the development of the metabolic 
syndrome in obesity with effects on glucose homeostasis, adipogenesis, insulin 
sensitivity and inflammation (41). Different concentrations of adenosine are required 
to activate different receptors in different tissues based on relative receptor abundance. 
This makes the response to adenosine both location and concentration dependent. 
WAT expresses A1, A3, A2a and A2b (from highest to lowest expression) of which 
A1 inhibits lipolysis and A2a increases lipolysis (41). This likely means that lower 
concentrations of adenosine are required to induce the effects of A1 than A2a giving 
net lipolysis inhibition at low concentrations. With increasing concentrations of 
adenosine, A2a receptors may be increasingly activated, overriding the effects of the 
A1 receptor and thereby leading to lipolysis stimulation. Experiments in primary cell 
cultures of human white adipocytes show that raising adenosine concentration above 
1000 μM or overexpressing the A2a receptor results in lipolysis but lower 
concentrations inhibit lipolysis (42). Which concentrations of adenosine is required 
for net lipolysis in 3T3-L1 cells is unknown. In our experiments we added at a 
maximum 200 nM of cAMP making it very unlikely that a concentration of 1000 μM 
adenosine is reached through conversion of the added cAMP. However, stimulation 
with cAMP might induce a cascade leading to expulsion of cAMP out of the cells. 
Dose-response experiments with adenosine on 3T3-L1 cells and measuring of cAMP 
and adenosine in growth medium after stimulation have to be performed to rule out 
A2a stimulation as the mechanism for lipolysis increase.  
To differentiate between effects from adenosine and cAMP at least two approaches 
can be applied. Either blocking conversion of cAMP to adenosine or blocking 
adenosine receptors would eliminate adenosine interference. cAMP conversion into 
adenosine occurs in two steps of which the second can be blocked with AMP-CP 
reducing the formation of adenosine and possibly maintaining higher concentrations 
of cAMP for a longer time. Our minor AMP-CP experiment generated however no 
significant results. An alternative approach is using DPSPX, a pan adenosine receptor 
antagonist which we have yet to test. 
7.2. ADENOSINE UPTAKE 
Lv et al demonstrated that in the vicinity of hepatocytes extracellular cAMP is 
converted into adenosine that is taken up via CNT2 causing up-regulation of CPT1a 
and Aox leading to increased fatty acid oxidation. Such mechanism does not require 
the presence of a cAMP receptor (30). Perhaps this mechanism exists and interferes 
with lipolysis in adipocytes. However, expression of genes involved in fatty acid 
oxidation and lipolysis and their proteins have not been quantified in our experiments. 
CNT2 can be blocked to rule out this mechanism as the reason for increased lipolysis. 
7.3. CAMP RECEPTORS 
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In case a mammalian receptor for extracellular cAMP exists and promotes lipolysis, 
low concentrations of cAMP are likely rapidly degraded leading to minimal cAMP 
binding to the receptors and larger activation of inhibitory adenosine receptors. In a 
setting with higher cAMP concentration complete degradation takes longer to occur 
leaving more time for cAMP to act on hypothesized receptors causing lipolysis. 
However, results in this study when pharmacologically blocking cAMP degradation 
with AMP-CP does not support this hypothesis. 
There is yet no evidence regarding presence of membrane bound cAMP receptors in 
mammals or that cAMP binds the PTHR (29). Methods to validate the existence of 
such a receptor could use binding assays with radiolabeled cAMP on PTHR-null cells 
or reverse genetics looking for reduction of cAMP binding to/interaction with cells in 
certain knock-outs. cAMP broken down in cells is reused in ATP production in order 
to reduce the need for energy demanding purine synthesis. Only smaller parts of 
cAMP transported out of cells is retaken - while the rest is secreted via urine - making 
it an energy demanding process. This suggests that extracellular cAMP has an 
important function.  
7.4. 3T3-L1 AS A MODEL OF ADIPOCYTES 
The 3T3-L1 cell line is a widely used model of adipocytes used in research in vitro. 
They have adipocyte-like capabilities such as adiponectin production as well as 
presence of adipocyte-specific organelles. However, 3T3-L1 adipocytes are generally 
not as sensitive to stimuli as primary adipocytes.  
Presence of lipolytic pathways and expected response to stimuli are considered 
markers for healthy cells and we tested this through insulin and β3 adrenergic receptor 
stimulation. Insulin stimulation decreased lipolysis and β3 adrenergic receptor 
stimulation increased lipolysis as expected.  
7.5. ERRORS 
The sample size of several groups in this study was very small making the results 
brittle. Sample sizes for both co-stimulation experiments and the groups 1 nM and 10 
nM in the dose-response experiment are 3 per group. Retrospective power analysis 
shows low power for several groups (10nM among them) but 100% power for 1nM 
group. 
In the dose response experiments results are not present when glycerol is not 
normalized to protein. In the co-stimulation experiments glycerol levels are not 
normalized to protein meaning a difference could perhaps be identified should values 
be normalized to protein. The protein normalization compensates for uneven cell 
density in wells and possibly also for uneven adipocyte differentiation. This study 
generated significant results only when protein normalization was applied, possibly 
indicating uneven distribution of cells. 
Not all cells included in the dose-response experiments were stimulated the same time 
after differentiation. Time for stimulation ranged between 1-3 days after full 
differentiation of adipocytes and this time is not noted nor analysed in the results. 
This difference in time could cause cells to change their susceptibility of lipolytic 
signals based on energy rich substrate concentrations in growth medium during time 
from differentiation to stimulation. Abundance of energy could cause cells to 
accumulate more fat and to be more susceptible to lipolytic signals. 
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Effects from cAMP stimulation on 3T3-L1 cells might differ between long term and 
acute stimulation. Incubation time of 180 minutes might be to long.  
 
7.6. CLOSING REMARKS 
Whatever the future has in store for the mammalian-CaR hypothesis one will never 
cease to be amazed by new capacities of old discoveries. cAMP has been at the center 
of massive amounts of laboratory and theoretical work for decades and yet this 
molecule manages to surprise us. As always, more research is needed.  
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Kan	molekylen	cAMP	hjälpa	dig	
bränna	fett?	
Fettväv	är	inte	de	flesta	människors	favoritorgan.	Fettväven	bär	dock	på	många	
hemligheter,	som	att	den	finns	i	2	huvudsakliga	typer	och	är	viktig	för	att	bevara	
god	hjärt-kärl	hälsa.	Vit	fettväv	är	en	aktiv	del	i	reglage	av	aptit,	påverkar	
insulinkänslighet	i	kroppen	samt	insulinsekretion	från	bukspottkörteln	vilket	
gör	fettväven	till	ett	viktigt	hormonutsöndrande	organ.	Vitt	fett	producerar	
dessutom	komponenter	i	komplementsystemet	som	ingår	i	immunförsvaret.	
Komplementsystemet	är	ett	infektionsförsvar	där	proteiner	lösta	i	blodet	binder	
bakterier	och	hjälper	till	att	bryta	ned	dem.	Brunt	fett	finns	huvudsakligen	hos	
nyfödda	och	små	däggdjur	för	att	reglera	kroppstemperatur.		
Frisättning	av	energi	från	fettväven	är	under	kontroll	av	nervsystemet	som	
samverkar	med	fettvävens	egna	reglage	vilket	baseras	på	blodsockernivåer	och	
andra	tecken	på	energibehov	i	kroppen.	När	väven	växer	blir	den	totala	
utsöndringen	av	hormon	större	och	förändrad,	vissa	hormon	minskar	och	andra	
ökar.	Både	hos	personer	med	för	mycket	fettväv,	som	vid	fetma,	och	för	lite,	som	
vid	grav	malnutrition,	uppstår	omställningar	i	kroppen	som	gör	det	mer	
sannolikt	att	utveckla	diabetes,	åderförfettning,	blodfettsrubbningar*	och	högt	
blodtryck;	denna	omställning	kallas	sammantaget	för	metabola	syndromet	vilket	
i	sin	tur	ökar	risken	för	stroke,	hjärtinfarkt	och	fönstertittarsjuka.	Gener	är	av	
stor	betydelse	för	vilka	effekter	fetma	ger	men	påverkar	inte	lika	starkt	
sannolikheten	att	utveckla	fetma.		
cAMP	är	en	molekyl	som	sedan	länge	är	känd	som	signalmolekyl	inuti	celler	med	
effekt	på	flertalet	biologiska	funktioner.	Rollen	cAMP	spelar	utanför	celler	är	
relativt	okänd	men	man	har	funnit	effekter	på	både	lever	och	njurar.	Leverns	
nedbrytning	av	fettsyror	ökaar	när	den	utsätts	för	cAMP.	Detta	gav	oss	idén	att	
undersöka	ifall	cAMP	kan	påverka	fettväv.	En	ökad	inblick	i	vita	fettvävens	
hantering	av	fettsyror	och	den	bruna	fettvävens	värmealstrande	kan	hjälpa	oss	
förstå	hur	fetma	kopplas	till	sjukdom	och	hur	man	kan	motverka	utveckling	av	
fetma	och	övervikt.		
För	att	testa	om	cAMP	påverkar	fettvävens	nedbrytning	och	frisättning	av	fett	
odlade	vi	i	labb	fram	fettceller	som	vi	utsatte	för	cAMP.	Sedan	mättes	
koncentrationen	restprodukter	från	fettnedbrytning	i	odlingsvätskan	cellerna	
omges	av.	Detta	visade	att	cAMP	i	låga	koncentrationer	motverkar	och	i	högre	
koncentrationer	stimulerar	fettnedbrytning.	Mekanismen	för	dessa	effekter	är	
dock	oklar	så	vägen	är	lång	till	ett	cAMP	preparat	som	hjälper	människor	
undvika	eller	reducera	fetma	och	dess	effekter.		
	
																																																								
*	Blodfetter	syftar	till	triglycerider	(som	är	fett)	och	transportproteiner	för	
triglycerider	och	kolesterol	kallade	high	density	lipoprotein	(HDL)	och	low	
density	lipoprotein	(LDL)	som	alltså	är	proteiner,	inte	fetter.	LDL	anses	dock		
spegla	kolesterolnivåerna	i	kroppen.	
 
